Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Immunome, Inc. - Common Stock
(NQ:
IMNM
)
20.45
-1.04 (-4.82%)
Streaming Delayed Price
Updated: 12:39 PM EST, Jan 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immunome, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Immunome Announces Pricing of Public Offering of Common Stock
December 16, 2025
From
Immunome, Inc.
Via
Business Wire
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
December 16, 2025
Issued on behalf of Oncolytics Biotech Inc.
From
Equity Insider
Via
GlobeNewswire
Why Immunome Stock Surged Today
↗
December 15, 2025
The oncology specialist's targeted therapies could improve thousands of lives.
Via
The Motley Fool
Where Immunome Stands With Analysts
↗
September 22, 2025
Via
Benzinga
Where Immunome Stands With Analysts
↗
September 05, 2025
Via
Benzinga
Immunome Announces Proposed Public Offering of Common Stock
December 15, 2025
From
Immunome, Inc.
Via
Business Wire
ENDRA Life Sciences (NASDAQ: NDRA) Advances Health Tech (Alongside KYTX, RADX, GLSI IMNM) With a Next-Generation Treasury Strategy
December 15, 2025
Via
AB Newswire
Which stocks are gapping on Monday?
↗
December 15, 2025
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.
Via
Chartmill
Immunome Stock Rises After Craig-Hellum Initiates Coverage With $26 Price Target: Here’s Why The Analyst Sees An ‘Attractive Entry Point’
↗
September 05, 2025
Via
Stocktwits
Why Is IMNM Stock Rising Today?
↗
December 15, 2025
Immunome stock is on track to open at its highest levels in over 20 months, after the company reported positive topline results from its global Phase 3 RINGSIDE trial for a treatment targeting a type...
Via
Stocktwits
Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
December 15, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors
December 14, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at Upcoming Investor Conferences
November 25, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update
November 06, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 04, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference
October 31, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance
October 23, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2025
From
Immunome, Inc.
Via
Business Wire
This Crocs Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday
↗
September 22, 2025
Via
Benzinga
This GATX Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
↗
September 22, 2025
Via
Benzinga
Infinimmune Announces Research Collaboration with Immunome
September 18, 2025
From
Infinimmune
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 03, 2025
From
Immunome, Inc.
Via
Business Wire
This Netgear Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
↗
August 22, 2025
Via
Benzinga
Immunome (IMNM) Q2 Revenue Surges 382%
↗
August 06, 2025
Via
The Motley Fool
Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update
August 06, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2025
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 03, 2025
From
Immunome, Inc.
Via
Business Wire
These stocks are moving in today's after hours session
↗
June 30, 2025
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
